Cipla

Cipla South Africa is one of the largest pharmaceutical companies in South Africa by volume and third largest by value. As part of its "Africa for Africa" strategy, and in line with ensuring equitable access to quality medication across the continent, Cipla is expanding its footprint across Africa. We want to unlock our continent’s wellbeing potential and drive inclusive economic growth. 

Over the last 90 years, we have strengthened our leadership in the pharmaceutical industry and fortified our promise of ‘Caring for Life’. We are trusted by healthcare professionals and patients across the world.

Ensuring equitable access
In 2001, Cipla introduced the world’s first-ever recommended 3-in-1 fixed-dose combination (stavudine + lamivudine + nevirapine) to fight AIDS. It was made available at less than $1 per day compared to over $12,000 per patient per year prevailing in most countries throughout the world, changing HIV from a perceived death sentence to a chronic disease which can be managed, and saving countless lives. In line with our ethos of care, we have done pioneering work across various therapeutic categories to ensure equitable access to quality, affordable medicine.

We want people to live a long and healthy life.

Our work is not just about making medicines. It’s about making a difference.

Product Range:
• OralAct Throat Spray
• OralAct Mouthwash
• Entiro Probiotic
• K-Fenak
• Ibugesic
• Oranix (Throat spray)
149 Oranix (Oral rinse)

Telephone Customer Care/Drug Safety: +27 80 222 6662
Medical Information Queries: med.info@Cipla.com
Adverse Events/Drug Safety: drugsafetysa@Cipla.com